| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Chemistry Officer | EVP, Head of Chemistry
1 company
Combs Andrew is a Chief Chemistry Officer at PRLD. Recent filings cover 6 purchases and 0 sales. Those positions are worth an estimated $332K at current prices.
Our model assigns Combs Andrew a middling insider score of 56/100, based on 5 past trades. Over a 12-month horizon, 60.0% of those trades were profitable, with an average 12-month return of +25.2%.
Combs Andrew's largest disclosed position is in PRLD as Chief Chemistry Officer, worth about $332K. Net of sales, the recent Form 4 record there shows accumulation of 172,075 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25, 2025 | PRLD Prelude Therapeutics Inc | Chief Chemistry Officer | Buy | 100,000 | $0.69 | $69,250.00 | +26.3% | +20.8% | +368.8% | |
| Dec 23, 2024 | PRLD Prelude Therapeutics Inc | Chief Chemistry Officer | Buy | 63,075 | $1.36 | $85,538.25 | +20.1% | -41.9% | +76.6% | |
| Dec 14, 2021 | PRLD Prelude Therapeutics Inc | EVP, Head of Chemistry | Buy | 8,000 | $11.86 | $94,880.00 | +3.1% | -34.8% | -56.3% | |
| Sep 29, 2020 | PRLD Prelude Therapeutics Inc | EVP, Head of Chemistry | Buy | 1,000 | $19.00 | $19,000.00 | +0.4% | - | - |